KOSDAQ Biotech Plunge Seen as 'Excessive Correction'... Selective Opportunities Resurface
Due to the sharp decline in major KOSDAQ-listed bio stocks, overall investment sentiment in the pharmaceutical and biotech sectors has weakened. However, the securities industry views this as a phase following excessive correction. Although volatility has increased due to short-term negative factors, many analysts believe the decline was excessive when considering the execution of core businesses and the results of new partnerships. There is also speculation that capital flows, which have recently concentrated on semiconductors, robotics, and automobiles, may become more diversified again.
In the market, global interest rate trends and the recovery of overseas biotech indices are being closely watched as key leading indicators. Experts advise that a selective approach is valid, especially for companies anticipating technology transfer or clinical milestones after annual global pharmaceutical and biotech events. There is also a growing view that recently plummeted stocks and companies that experienced high volatility early after listing may present mid- to long-term opportunities.
[Industry leader HiStockLoan: https://www.hisl.co.kr/5113]
Meanwhile, interest in stock loans continues to rise. Investors who do not want to miss out on rare investment opportunities are turning to stock loans, which allow them to utilize more capital for stock purchases.
One of the advantages of stock loans is that even if investors face a forced sale crisis due to a sharp drop in stock prices while using margin or credit, they can simply switch products without providing additional collateral or selling stocks, and wait for a rebound.
◆ HiStockLoan: Additional investment funds and credit refinancing available at the industry's lowest annual interest rate of 4%!
HiStockLoan has launched a securities-linked credit product that is accessible to everyone at an industry-low annual interest rate in the 4% range, allowing investors to experience stock loans with ease. It can be used for stock purchases as well as refinancing margin or credit from securities firms, and up to four times the investor's own capital can be utilized regardless of credit rating.
Additionally, for investors who previously had difficulty using stock loans due to DSR (Debt Service Ratio) limits, products that can be used regardless of DSR are also available. Investors using the alternative trading system (NXT) can also take advantage of these offerings.
Investors interested in HiStockLoan's diverse, customized products can contact the customer service center (☎1566-5113) at any time, 24 hours a day, for convenient consultations with professional advisors, regardless of whether they take out a loan.
○ Industry-low annual interest rate products in the 4% range launched
○ DSR-free products available
○ No. 1 market share for 22 consecutive years, First Brand Award in Korea for 17 consecutive years
○ Real-time repayment of margin/credit with securities firms
○ Trading available on the alternative trading system (NXT)
○ Reliable consultation quality assurance system
* HiStockLoan Consultation Center: 1566-5113
Go to: https://www.hisl.co.kr/5113
Hyundai Motor, Samsung Electronics, Alteogen, Samsung SDI, Hurim Robotics
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.